Clinical Trial Oversight Must Focus On Major Risks, FDA Says
The U.S. Food and Drug Administration on Tuesday advised drugmakers and medical device firms to fine-tune their oversight of clinical trials by focusing on the most important risks and advised manufacturers...To view the full article, register now.
Already a subscriber? Click here to view full article